Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress
Envoy Medical reported Q3 2026 revenue of $66 thousand (up from $42 thousand) with a net loss attributable to common stockholders of $5.24 million, or $0.50 per share, narrowed from $7.75 million, or $3.55, a year ago. The clinical pipeline advanced materially: the first 10 pivotal-trial participants achieved a mean CNC word recognition score of 53.2% at 12 months versus a 15.2% baseline, and all 56 patients have passed the six-month follow-up milestone, with 12-month visits expected to complete by early Q2 2027.
Key figures
- Revenue
- 66000
- Guidance
- All Stage 2 participants expected to complete 12-month data collection by early Q2 2027; final PMA module submission planned a few months thereafter
- Revenue Yoy
- 57%
- Cash
- 14570000
- Cnc baseline
- 15.2%
- Trial patients
- 56
- G and a expense
- 2125000
- Granted patents
- 97
- R and d expense
- 3077000
- Cost of goods sold
- 244000
- Cnc word recognition 12mo
- 53.2%
- Pending patent applications
- 35
- Sales and marketing expense
- 157000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.